Clinerion announced that it has been selected as a finalist in the Fierce Innovation Awards – Life Sciences Edition 2020, a peer reviewed awards program from the publisher of Fierce Biotech and Fierce Pharma, produced by Questex.
The competition highlights companies that demonstrated innovative solutions, technologies, and services that have the potential to make the greatest impact for biotech and pharma companies. Clinerion?was recognized as a finalist in the category of? Data Analytics/Business Intelligence.
Clinerion was selected as a finalist for its innovative, industry-leading real-world data service solutions for the generation of real-world evidence (RWE) and health economics and outcomes research (HEOR) on its Patient Network Explorer platform, in particular for real-world data for COVID-19.
These services are based on patient data queried and aggregated directly from the anonymized, aggregated real-time patient electronic health records (EHRs) from the millions of patients around the world in the global network of partner hospitals on Clinerion’s Patient Network Explorer platform. This resource allows users to generate insights on the patient journey, treatments and outcomes, by applying intelligent, patented informatics methodologies to interpret information from large amounts of EHRs. This powerful platform facilitates longitudinal epidemiological studies, allowing a focused search of patient characteristics or treatment patterns, as well as patient, physician and site outreach.
In the battle against COVID-19, researchers and health authorities require immediate patient data from a global perspective on disease transmittance, cohorts, and success rates for treatment regimes, among many other indicators. Patient Network Explorer supports research and RWE for COVID-19 cases, as well as for conditions that are associated with SARS-CoV-2 infections.
The awards program’s applications were reviewed by an exclusive panel of executives from major biotech and pharma companies including Astellas, Accenture, AstraZeneca, Angiocrine Bioscience, Biotech Research Group, NIHR Clinical Research Network, Medidata Solutions and PPD. All applications were evaluated based on the following criteria: effectiveness, technical innovation, competitive advantage, financial impact, and true innovation.
Winners will be announced in the 2020 Innovation Report set to publish by Fierce Life Sciences on September 14, 2020.
”Our main objective is to be able to support good outcomes for patients and their physicians around the world with our technology, especially in the age of COVID-19, when researchers are so desperate for robust, usable data,” says Ian Rentsch, CEO of Clinerion. “To have this recognized by the Fierce Innovation Awards and leaders of the industry is a very nice icing on the cake.”
About Clinerion
Clinerion accelerates clinical research and medical access to treatments for patients. We generate real-world data from our global network of partner hospitals for Real World Evidence analyses. Clinerion’s Patient Network Explorer radically improves the efficiency and effectiveness of clinical trial recruitment by offering data-driven protocol optimization, site feasibility evaluation and real-time patient search and identification to match patients to treatments.
Clinerion facilitates the participation of partner hospitals in leading-edge, industry-sponsored trials and time savings in patient recruitment. Researchers gain access to real-time, longitudinal patient data from electronic health records for analysis. We enable pharmaceutical companies, CROs and SMOs to shorten patient recruitment and save costs by streamlining operations and leveraging strategic intelligence. Clinerion’s Patient Network Explorer also provides a platform for integration of diverse patient data sources into real-world data ecosystems. Clinerion’s proprietary technologies comply with international patient privacy and data security regulations. Clinerion is a global data technology service company headquartered in Switzerland.
